Stocks Health care CNTX
NASDAQ · Health careContext Therapeutics Inc. (CNTX)
It posted a net loss of $46M. In fiscal 2025 capital spending exceeded operating cash flow by $26.4M. At June 30, 2026 it held $43M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
Key facts about Context Therapeutics Inc.
- Net worth
- Context Therapeutics Inc. has a market value (market cap) of $18.4M at the latest share price, and shareholders' equity of $38.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $26.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 5, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Context Therapeutics Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What Context Therapeutics Inc. does
Context Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CNTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$36.1M | -$0.38 | -$26.4M |
| 2024 | n/a | -$26.7M | -$0.46 | -$14.6M |
| 2023 | n/a | -$24M | -$1.50 | -$21M |
| 2022 | n/a | -$14.8M | -$0.93 | -$13.6M |
| 2021 | n/a | -$10.5M | -$3.69 | -$8.8M |
| 2021 | n/a | $6.6M | -$3.96 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Context Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026
- August 5, 2026
- July 31, 2026
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- June 26, 2026
- June 15, 2026
- May 18, 2026
Insider trades
What the people running Context Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns CNTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Avidity Private Master Fund I LP13G, passive with 7 related filers | 9.9% | November 14, 2024 |
| Avidity Partners Management LP13G, passive with 5 related filers | 8.7% | May 12, 2026 |
| Deep Track Capital, LP13G, passive with 2 related filers | 8.27% | May 15, 2025 |
| Soleus Capital Master Fund, L.P.13G, passive with 5 related filers | 7.6% | May 8, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 79 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nextech Invest Ltd. | 7,419,355 | 0 |
| Deep Track Capital, LP | 7,419,355 | 0 |
| Soleus Capital Management, L.P. | 7,063,141 | +100,000 |
| BlackRock, Inc. | 6,169,250 | +5,322,554 |
| Avidity Partners Management LP | 4,998,267 | -4,998,267 |
| Franklin Resources Inc | 3,803,338 | 0 |
| Vanguard Capital Management LLC | 3,432,052 | +99 |
| Octagon Capital Advisors LP | 3,050,000 | -2,200,000 |
| Blue Owl Capital Holdings LP | 2,934,015 | -2,155,000 |
| TCG Crossover Management, LLC | 2,682,696 | 0 |
| Geode Capital Management, LLC | 1,830,309 | +1,226,542 |
| State Street Corp | 1,413,428 | +1,179,921 |
| Mpm Bioimpact LLC | 1,299,046 | -9,380,345 |
| Renaissance Technologies LLC | 1,041,399 | +858,400 |
| ADAR1 Capital Management, LLC | 750,969 | +399,875 |
| Jane Street Group, LLC | 645,209 | +208,278 |
| Vanguard Portfolio Management LLC | 638,878 | new |
| Northern Trust Corp | 615,576 | +512,320 |
| Vanguard Fiduciary Trust Co | 433,888 | +92,544 |
| Marshall Wace, Llp | 384,528 | -2,563,913 |
Insiders
Questions about CNTX
What does Context Therapeutics Inc. do?
Context Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as CNTX. Its shares trade on NASDAQ under the ticker CNTX.
What is Context Therapeutics Inc.'s net worth?
Context Therapeutics Inc. has a market value (market cap) of $18.4M at the latest share price, and shareholders' equity of $38.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Context Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $46M.
When did Context Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.
When is Context Therapeutics Inc.'s next earnings report?
Context Therapeutics Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare CNTX with
Follow CNTX
Get an email when Context Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Context Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.